Actavis, Warner Chilcott
Actavis, Inc. will have to sell the rights and assets to three oral contraceptives and an osteoporosis treatment in exchange for the right to buy Warner Chilcott for $8.5 billion, under...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login
to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information:
FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch